Recombinant Human Siglec-6/CD327 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human Siglec-6/CD327 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to bind biotinylated Neu5Ac alpha 2-6GalNAc alpha (sialyl-Tn). Patel, N. et al. (1999) The Journal of Biological Chemistry 274:22729.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Siglec-6/CD327 protein
  

  Human Siglec-6 (Gln27-Val331) Accession # NP_942142	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: NP_942142
• N-terminal Sequence: No results obtained: Gln27 predicted
• Protein/Peptide Type: Recombinant Proteins
• Gene: SIGLEC6
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 60.3 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 80-95 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Siglec-6/CD327 Fc Chimera Protein, CF

• CD327 antigen
• CD327
• CD33 antigen-like 1
• CD33L1
• CD33L1OBBP1CD327
• CD33L2
• CD33LCDW327
• CDw327
• OB-BP1
• Obesity-binding protein 1
• sialic acid binding Ig-like lectin 6
• sialic acid-binding Ig-like lectin 6
• Siglec6
• Siglec-6

Background

Siglecs (sialic acid binding Ig-like lectins) are I-type (Ig-type) lectins that belong to the Ig superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains (1 - 4). Eleven human Siglecs (Siglec-1 through 11) have been cloned and characterized. Within these eleven, there are at least two groups, one of which is termed the CD33-related group. CD33-related Siglecs include CD33/Siglec-3 and Siglec-5 through 11 (1, 3). To date, no Siglec has been shown to recognize any cell surface ligand other than sialic acid. This suggests that interactions with glycans containing this carbohydrate are important in mediating the biological functions of Siglecs. The cDNA of human Siglec-6 (also known as OB-BP1 and CD33L), encodes a putative 442 amino acid (aa) protein that contains a 15 aa signal peptide, a 321 aa extracellular region, a 21 aa transmembrane region (TM), and an 85 aa cytoplasmic tail (5, 6). The extracellular region contains one N-terminal V-type Ig-like domain followed by two Ig-like C2-type domains. The cytoplasmic domain has one immunoreceptor tyrosine-based inhibition motif (ITIM). At least three additional isoforms exist, all of which encode an additional 11 aa’s at the N-terminus, likely due to the utilization of an alternate start site. Two of the three isoforms also show splicing. One isoform shows a 16 aa in-frame deletion in the second C2-like domain, while the other shows a deletion of the TM and cytoplasmic region, thus potentially generating a soluble form (6 - 9). Siglec-6 is found on B cells and in placenta, and would seem to have a restricted specificity for the sialyl Tn antigen (6, 10).

1. Crocker, P.R. and J. Zhang (2002) Biochem. Soc. Symp. 69:83.
2. Crocker, P.R. and A. Varki (2001) Immunology 103:137.
3. Crocker, P.R. (2002) Curr. Opin. Struct. Biol. 12:609.
4. Powell, L.D. and A. Varki (1995) J. Biol. Chem. 270:14243.
5. Takei, Y. et al. (1997) Cytogenet. Cell Genet. 78:295.
6. Patel, N. et al. (1999) J. Biol. Chem. 274:22729.
7. GenBank Accession # NP_942143.
8. GenBank Accession #: NP_942142.
9. GenBank Accession #: NP_001236.
10. Crocker, P.R. and A. Varki (2001) Trends Immunol. 22:337.

Publications for Siglec-6/CD327 (2859-SL)(3)

Publications using 2859-SL

• D Kovalovsky, JH Yoon, MG Cyr, S Simon, E Voynova, C Rader, A Wiestner, J Alejo, S Pittaluga, RE Gress Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia Leukemia, 2021-02-25;0(0):. 2021-02-25 [PMID: 33633313] (Bioassay, Human)
• Chen , Guo-Yun, Brown , Nicholas, Wu , Wei, Khedri , Zahra, Yu , Hai, Chen , Xi, van de Vlekkert , Diantha, D'Azzo , Alessand, Zheng , Pan, Liu , Yang Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1. Elife, 2014-09-03;3(0):e04066. 2014-09-03 [PMID: 25187624] (Bioassay, Human)
• Lam KK, Chiu PC, Lee CL Glycodelin-A protein interacts with Siglec-6 protein to suppress trophoblast invasiveness by down-regulating extracellular signal-regulated kinase (ERK)/c-Jun signaling pathway. J. Biol. Chem., 2011-08-31;286(43):37118-27. 2011-08-31 [PMID: 21880722] (Binding Assay, Human)

Bioinformatics

• Gene Symbol: SIGLEC6
• Uniprot:
  • NP_942142()